In the news

Cerevel Therapeutics Strengthens Leadership Team with the Appointment of Orly Mishan as Chief Business Officer

Ms. Mishan Brings a Wealth of Business Development and Corporate Strategy Expertise to the Company

BOSTON, Mass. – August 14, 2019 – Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Orly Mishan as chief business officer. In this newly created role, Ms. Mishan will lead corporate development, program management, and technical operations while contributing to the advancement of the company’s strategy as a member of the executive leadership team.

Ms. Mishan joins Cerevel Therapeutics from Bain Capital Life Sciences where she served as principal, overseeing investments in biopharmaceutical, medical device, diagnostics, and enabling technology companies. She was a founding member of the Bain Capital Life Sciences team and helped execute the partnership with Pfizer that led to the formation of Cerevel Therapeutics.

“Orly is a seasoned biopharmaceutical executive with an established record of leading business development, strategic planning, and building companies with strong cultures,” said Tony Coles, M.D., executive chairperson of Cerevel Therapeutics. “Given her knowledge of the legacy Pfizer programs and oversight of the company’s creation, Orly will be a vital member of the leadership team as we accelerate and grow our portfolio of leading solutions for people living with devastating neuroscience diseases.”

“Difficult-to-treat neuroscience diseases take an extensive toll on the lives of people touched by these conditions and society as a whole—problems that will be exacerbated as the global population ages,” said Ms. Mishan. “Cerevel Therapeutics is purpose-built to progress neuroscience therapies in a sustainable way, and I look forward to working with the team to advance the science internally and through external collaborations.”

About Orly Mishan

Prior to joining Bain Capital Life Sciences, Ms. Mishan was the vice president of corporate strategy at Biogen. She spent more than 10 years at Boston Scientific in leadership roles supporting strategy, transaction and restructuring activities, and spearheading the development of the global healthcare services business. Ms. Mishan started her career as a business analyst at McKinsey & Company and later helped lead interdisciplinary transaction and product development teams at Pfizer. She earned a Bachelor of Arts in economics and political science from Columbia University.

About Cerevel Therapeutics

Cerevel Therapeutics ( is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is unlocking new treatment opportunities by understanding the neurocircuitry of symptoms. Cerevel Therapeutics has a diversified pipeline comprising three clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including epilepsy, Parkinson’s, Alzheimer’s, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel Therapeutics is fueled to advance its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or acquisitions.

Media Contact:

Rachel Eides
W2O pure